Show simple item record

dc.contributor.authorPatel, Sarah
dc.creatorPatel, Sarah
dc.date.accessioned2020-06-17T01:31:26Z
dc.date.available2020-06-17T01:31:26Z
dc.date.issued2020
dc.identifier.urihttp://hdl.handle.net/10150/641626
dc.descriptionA Thesis submitted to The University of Arizona College of Medicine - Phoenix in partial fulfillment of the requirements for the Degree of Doctor of Medicine.
dc.description.abstractObjective: 1) Compare trends in mean arterial blood pressures and vasoactive-inotropic scores of pediatric patients after treatment of hypotension with methylene blue compared to controls; 2) Describe the dose administered and the pathologies of hypotension cited for methylene blue use; 3) Compare the morbidity and mortality of pediatric patients treated with methylene blue versus controls. Design: A retrospective chart review. Setting: Cardiac ICU in a quaternary care free-standing children’s hospital. Patients: Thirty-two patients with congenital heart disease who received methylene blue as treatment for hypotension, fifty patients with congenital heart disease identified as controls. Interventions: None. Measurements and Main Results: Demographic and vital sign data was collected for all pediatric patients treated with methylene blue during a three year period. Linear regression models examined trends in mean arterial blood pressures twelve hours post methylene blue treatment and vasoactive-inotropic scores for twenty-four hours post treatment. Methylene blue treatment correlated with an increase in mean arterial blood pressure of 10.8mm Hg over a twelve hour period (p< 0.001). Mean arterial blood pressure trends of patients older than one year did not differ significantly from controls (p=0.79), but patients less than or equal to one year of age had increasing mean arterial blood pressures that trended toward significance compared to controls (p=0.07). Similarly, a statistically significant decrease in vasoactive-inotropic scores was observed over a twenty-four hour period (?= -0.62, p< 0.001, ECMO ?= -6.07, p= 0.029). This difference remained significant compared to controls (p=0.001). Survival estimates did not detect survival differences between the groups (p=0.5). Conclusion: Methylene blue may be associated with a decreased need for vasoactive-inotropic support and may correlate with an increase in mean arterial blood pressure in patients who are less than or equal to one year of age.
dc.language.isoen
dc.publisherThe University of Arizona.
dc.rightsCopyright © is held by the author. Digital access to this material is made possible by the College of Medicine - Phoenix, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/
dc.subjectPediatrics
dc.subjectSurgery
dc.subjectCardiology
dc.subjectmethylene blue
dc.subjectvasoplegia
dc.subjectpediatric cardiac surgery
dc.subjectcongenital heart disease
dc.subject.meshPediatrics
dc.subject.meshCardiology
dc.titleMethylene Blue Use in Pediatric Patients in the Cardiovascular Intensive Care Unit
dc.typetext
dc.typeElectronic Thesis
dc.typePoster
dc.description.collectioninformationThis item is part of the College of Medicine - Phoenix Scholarly Projects 2020 collection. For more information, contact the Phoenix Biomedical Campus Library at pbc-library@email.arizona.edu.
dc.contributor.mentorWillis, Brigham C.
refterms.dateFOA2020-06-17T01:31:26Z


Files in this item

Thumbnail
Name:
SP_2020_Patel_Thesis.pdf
Size:
348.3Kb
Format:
PDF
Thumbnail
Name:
SP_2020_Patel_Poster.pdf
Size:
455.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record